In the mouse model, the deletion of Arhgef1 inhibits Ang II-dependent immune cell activation and their recruitment to the arterial endothelium, which suggests that the Arhgef1 can be a novel target for therapeutic intervention in atherosclerosis [71]. This evidence concerns the gene ARHGEF1 and atherosclerosis.